A Phase3, Multi-center, Open-label Study to Test the Diagnostic Performance of Copper Cu64PSMAI & TPET/CT in Men with Biochemical Recurrence of Prostate Cancer (SOLAR 002) and A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk, or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection (SOLAR 003)
These studies are both prospective, Phase 3 studies
SOLAR 002 focuses on determining the accuracy of copper Cu 64 PSMA I&T PET/CT in the diagnosis of biochemical recurrence of prostate cancer.
SOLAR 003 focuses on determining the safety and effectiveness of Copper Cu 64 PSMA I&T Injection as an imaging agent in the staging of men with newly diagnosed prostate cancer in those electing to undergo radical prostatectomy with extended pelvic lymph node dissection.
SOLAR 002 focuses on determining the accuracy of copper Cu 64 PSMA I&T PET/CT in the diagnosis of biochemical recurrence of prostate cancer.
SOLAR 003 focuses on determining the safety and effectiveness of Copper Cu 64 PSMA I&T Injection as an imaging agent in the staging of men with newly diagnosed prostate cancer in those electing to undergo radical prostatectomy with extended pelvic lymph node dissection.
Principal Investigator: Dr. Medhat Osman
Study Coordinator: Brittany Minor
These projects are both in the study start up phases and will soon be enrolling new patients.
To learn more about either SOLAR trials and how you can join contact our research office at (314) 289-7690.
These studies are funded by the Foundation through the sponsor CURIUM
Study Coordinator: Brittany Minor
These projects are both in the study start up phases and will soon be enrolling new patients.
To learn more about either SOLAR trials and how you can join contact our research office at (314) 289-7690.
These studies are funded by the Foundation through the sponsor CURIUM